Back to search results

Mobile Health Intervention for Exercise in Pediatric Pulmonary Hypertension

This study is testing a mobile health (mHealth) intervention to help children and young adults with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) increase their daily activity. The mHealth intervention uses a texting platform linked to your smartphone to send you messages throughout the day. Researchers want to see if this intervention can increase your average daily step count over 12 weeks, compared to usual care. You might be able to join if you are 10 to 21 years old, have WHO Group 1 PAH or WHO Group 4 PH, and your PAH medications have been stable for at least three months. This study plans to enroll 50 participants.

Study design
This is an interventional study comparing a mobile health intervention to usual care. It plans to enroll 50 participants.
What's involved
Participants will use a smartphone-linked texting platform for the mHealth intervention. The primary endpoint is measured from baseline to 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 12 weeks after baseline.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06549452

Mobile Health Intervention to Improve Exercise in Pediatric PH

Recruiting
NAAges 10–21InterventionalTreatment
Vanderbilt University Medical Center
~50 participants
Updated 2026-03-27 on ClinicalTrials.gov
What's tested:mHealth InterventionUsual Care

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in average daily step count from baseline to 12 weeks
Measured over Baseline to 12 weeks

Conditions

Pulmonary Arterial Hypertension

Explore related trials

Pulmonary Arterial Hypertension

NCT06549452

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Vanderbilt University Medical Center

    Nashville, Tennesseestudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Eric Austin, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center

Who to contact

Natasha Billard
[email protected]
(434) 851-3306
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adolescents between ages 10-21 years.
Diagnosed with WHO Group 1 PAH or WHO Group 4 PH (CTEPH)
WHO functional class I-III
Stable PAH-specific medication regimen for three months prior to enrollment. Subjects with only a single diuretic adjustment in the prior three months will be included. Adjustments in IV prostacyclin for side effect management are allowed.

Exclusion

Prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other condition that limits activity.
Pregnancy
Diagnosis of PAH etiology other than idiopathic, heritable, or associated.
Functional class IV heart failure
Requirement of \> 2 diuretic adjustment in the prior three months.
Preferred form of activity is not measured by an activity tracker (swimming, yoga, ice skating, stair master, or activities on wheels such as bicycling or rollerblading).
Involved in any other investigational intervention.

What this trial measures

  • Change in average daily step count from baseline to 12 weeksBaseline to 12 weeks

    To assess the effect of a mHealth intervention or no intervention on average daily step count from baseline to 12 weeks. Accelerometry is a direct measure of physical activity in patients' day-to-day lives. Step counts will be measured using the Fitbit device monitor, a lightweight device that has a three-axis acceleration sensor, altimeter, vibration motor, and optical heart rate monitor.